- Home
- LVTX vs NOTV Comparison
LVTX vs NOTV Comparison
Compare LVTX & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- NOTV
- Stock Information
- Founded
- LVTX 2016
- NOTV 1974
- Country
- LVTX Netherlands
- NOTV United States
- Employees
- LVTX N/A
- NOTV N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- NOTV Health Care
- Exchange
- LVTX Nasdaq
- NOTV Nasdaq
- Market Cap
- LVTX 40.0M
- NOTV 46.7M
- IPO Year
- LVTX 2021
- NOTV 1997
- Fundamental
- Price
- LVTX $1.58
- NOTV $1.35
- Analyst Decision
- LVTX Hold
- NOTV Strong Buy
- Analyst Count
- LVTX 4
- NOTV 1
- Target Price
- LVTX $1.58
- NOTV $5.00
- AVG Volume (30 Days)
- LVTX 513.1K
- NOTV 294.1K
- Earning Date
- LVTX 12-09-2025
- NOTV 12-02-2025
- Dividend Yield
- LVTX N/A
- NOTV N/A
- EPS Growth
- LVTX N/A
- NOTV N/A
- EPS
- LVTX N/A
- NOTV N/A
- Revenue
- LVTX $4,990,000.00
- NOTV $505,299,000.00
- Revenue This Year
- LVTX N/A
- NOTV $5.64
- Revenue Next Year
- LVTX N/A
- NOTV $5.16
- P/E Ratio
- LVTX N/A
- NOTV N/A
- Revenue Growth
- LVTX N/A
- NOTV 0.85
- 52 Week Low
- LVTX $0.85
- NOTV $1.15
- 52 Week High
- LVTX $2.06
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- LVTX 53.29
- NOTV 43.83
- Support Level
- LVTX $1.58
- NOTV $1.29
- Resistance Level
- LVTX $1.63
- NOTV $1.47
- Average True Range (ATR)
- LVTX 0.06
- NOTV 0.10
- MACD
- LVTX 0.01
- NOTV 0.00
- Stochastic Oscillator
- LVTX 72.99
- NOTV 40.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.